Please assess the completion status of the following clinical trial:

Trial Title: Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged =/\> 18 years~* Subjects with advanced, histologically or cytologically confirmed advanced malignancies (solid tumors), refractory to any standard therapy, have no standard therapy available, or subjects actively refused any standard treatment and / or if, in the judgment of the investigator, experimental treatment is clinically and ethically acceptable.~* For the expansion cohort: women with histologically or cytologically confirmed triple negative breast cancer (TNBC)~* Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1~* Life expectancy of at least 12 weeks~* Adequate bone marrow, liver, and renal functions~Exclusion Criteria:~* Known hypersensitivity to the study drugs or excipients of the preparations or any agent given in association with this study~* Evidence of peripheral neuropathy of Grade \> 2~* History of cardiac disease: congestive heart failure New York Heart Association (NYHA) class \> II, unstable angina (anginal symptoms at rest), new-onset angina (within the past 3 months before study entry), myocardial infarction within the past 3 months before study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers, calcium channel blockers, and digoxin are permitted)~* Prior treatment with more than 3 lines of cytostatic therapies for metastatic disease unless specifically agreed between investigator and sponsor. Subjects with a history of any prior Grade =/\> 3 toxicity associated with taxane treatment will be excluded.~* Uncontrolled hypertension defined as systolic blood pressure \>150 mmHg or diastolic blood pressure \>90 mmHg, despite optimal medical management~* Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C~* History of human immunodeficiency virus (HIV) infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BAY1161909 + Paclitaxel (Type: EXPERIMENTAL): Participants received oral doses of BAY1161909 starting from 0.75 mg twice daily, from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in combination with weekly intravenous paclitaxel on D1, D8, and D15 of the 28-day cycles. For single-dose Pharmacokinetic (PK) cohort: in Cycle 1, participants received a single oral dose of 6 mg BAY1161909 on C1D1 with no BAY1161909 dosing for the remainder of Cycle 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).